5-(2-bromophenyl)-1,3,4-oxadiazol-2(3H)-one | 1044766-10-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-(2-bromophenyl)-1,3,4-oxadiazol-2(3H)-one
• 英文别名: 5-(2-Bromophenyl)-1,3,4-oxadiazol-2-ol；5-(2-bromophenyl)-3H-1,3,4-oxadiazol-2-one
• CAS: 1044766-10-0
• 化学式: C₈H₅BrN₂O₂
• 分子量: 241.044
• InChiKey: LLXKEYIVXPRCCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-(2-bromophenyl)-1,3,4-oxadiazol-2(3H)-one 、 二甲胺 在 三乙胺 、 对甲苯磺酰氯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 16.0h， 生成 5-(2-Brom-phenyl)-2-dimethylamino-1.3.4-oxadiazol
  参考文献：
  名称：

  INHIBITORS OF FATTY ACID AMIDE HYDROLASE

  摘要：

  本发明提供了由任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物及其药学上可接受的组合物所包含的范围，或其亚属所包含的范围。本发明还提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来治疗FAAH介导的疾病、紊乱或症状的方法。此外，本发明提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来抑制FAAH的方法。

  公开号：

  US20150368278A1
• 作为产物：
  描述：

  tert-butyl N-[(2-bromophenyl)methylideneamino]carbamate 在 N-氯代丁二酰亚胺 作用下， 以 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.2h， 生成 5-(2-bromophenyl)-1,3,4-oxadiazol-2(3H)-one
  参考文献：
  名称：

  Synthesis of 5-aryl-3H-[1,3,4]oxadiazol-2-ones from N′-(chloro-aryl-methylene)-tert-butylcarbazates using basic alumina as an efficient and recyclable surface under solvent-free condition

  摘要：

  The synthesis of biologically important 5-aryl-3H-[1,3,4]oxadiazol-2-ones has been carried out by heating the easily synthesized N'-(chloro-aryl-methylene)-tert-butylcarbazates on basic alumina surface under solvent-free condition. The dual characteristic of basic alumina as a solid support as well as a nucleophile is successfully exploited in these reactions. The method provides special attributions such as reduced reaction times, easier work-up procedures, and good to excellent yields as well as increased purity of products and most importantly environmentally friendly protocols. The basic alumina is easily recovered and utilized for further reactions several times without serious loss of activity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2012.11.128

文献信息

• Electrochemically promoted annulation of aldehydes and carbazates: access to 2-alkoxy/aryloxy-5-substituted 1,3,4-oxadiazole and 1,3,4-oxadiazol-2(3<i>H</i>)-one derivatives
  作者：Hongjun Li、Dong Tang、Zafar Iqbal、Yaya Wan、Rui Jiang、Zhixiang Yang、Jinhui Yang

  DOI：10.1039/d2nj04113h

  日期：——

  The strategy is oxidant-free and transition-metal free, offering the electrolyte-free completion of the reaction at room temperature. A possible mechanism has been proposed based on control-experiment results and literature reports. The practical utility of this approach is highlighted via the brief synthesis of 5-(4-chloro-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2(3H)-one, which is a potent inhibitor

  通过醛的环化，开发了一种高效且环保的化学和药学上有趣的 2-烷氧基/芳氧基-1,3,4-恶二唑和 1,3,4-恶二唑-2(3 H )-酮的合成方法和卡巴酸盐。该协议涉及以电化学方式促进以良好至优异的产量获得所需产品。该方法使用 NaBr 作为电催化剂，MeOH 作为溶剂。该策略不含氧化剂和过渡金属，可在室温下无电解质完成反应。基于对照实验结果和文献报道提出了一种可能的机制。通过5-(4-chloro-3-(trifluoromethyl)phenyl)-1,3,4-oxadiazol-2( 3 H)-one，它是 Notum 羧酸酯酶活性的有效抑制剂。
• INHIBITORS OF FATTY ACID AMIDE HYDROLASE
  申请人：INFINITY PHARMACEUTICALS, INC.

  公开号：US20150368278A1

  公开（公告）日：2015-12-24

  The present invention provides compounds, and pharmaceutically acceptable compositions thereof, encompassed by any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof. The present invention also provides methods for treating an FAAH mediated disease, disorder or condition by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof. Additionally, the present invention provides methods for inhibiting FAAH by administering a therapeutically effective amount of a compound or composition comprising a compound of any of formulae (I), (II), (III), (IV), (V), or (VI), or subgenera thereof, to a patient in need thereof.

  本发明提供了由任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物及其药学上可接受的组合物所包含的范围，或其亚属所包含的范围。本发明还提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来治疗FAAH介导的疾病、紊乱或症状的方法。此外，本发明提供了通过向需要的患者投与任何公式（I）、（II）、（III）、（IV）、（V）或（VI）中的任何化合物或其组合物的治疗有效量来抑制FAAH的方法。
• Synthesis of 5-aryl-3H-[1,3,4]oxadiazol-2-ones from N′-(chloro-aryl-methylene)-tert-butylcarbazates using basic alumina as an efficient and recyclable surface under solvent-free condition
  作者：Kamalesh Debnath、Sudipta Pathak、Animesh Pramanik

  DOI：10.1016/j.tetlet.2012.11.128

  日期：2013.2

  The synthesis of biologically important 5-aryl-3H-[1,3,4]oxadiazol-2-ones has been carried out by heating the easily synthesized N'-(chloro-aryl-methylene)-tert-butylcarbazates on basic alumina surface under solvent-free condition. The dual characteristic of basic alumina as a solid support as well as a nucleophile is successfully exploited in these reactions. The method provides special attributions such as reduced reaction times, easier work-up procedures, and good to excellent yields as well as increased purity of products and most importantly environmentally friendly protocols. The basic alumina is easily recovered and utilized for further reactions several times without serious loss of activity. (C) 2012 Elsevier Ltd. All rights reserved.